NCT03753776View on ClinicalTrials.gov

Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women

PHASE3CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

January 5, 2024

Study Completion Date

April 5, 2024

Conditions
Breast Cancer
Interventions
DRUG

Placebo pills of Radium bromatum

Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition

DRUG

Radium bromatum pills

Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition

DRUG

Radium bromatum/Apis mellifica/Belladonna placebo pills

Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation

DRUG

Radium bromatum/Apis mellifica/Belladonna pills

Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation

Trial Locations (1)

42055

CHU de Saint-Etienne, Saint-Etienne

All Listed Sponsors
collaborator

Institut de Cancérologie de la Loire

OTHER

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT03753776 - Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women | Biotech Hunter | Biotech Hunter